What one share of Adaptin Bio holds
We are a biopharmaceutical company pioneering a transformational approach to enhance the transfer of therapeutics into the brain, facilitating the treatment of brain cancers and other unmet medical conditions. The Company’s proprietary technology harnesses the human immune system’s ability to target, recognize, destroy or deliver therapeutics to specific cells, including cancer cells.
Adaptin Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.63 |
|---|---|
| Cash and investments | $0.07 |
| Book value | −$0.18 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$0.02 | — | — | — | −$0.20 |
| 2024 | — | −$0.96 | — | — | — | −$1.26 |
| 2025 | — | −$0.66 | — | — | — | −$0.17 |
Common questions about Adaptin Bio
How much does one share of Adaptin Bio earn?
Over the last 12 months, Adaptin Bio lost $0.63 for each share.
Does Adaptin Bio pay a dividend?
Adaptin Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Adaptin Bio’s book value per share?
Adaptin Bio’s book value is negative (−$0.18 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Adaptin Bio have?
Each share of Adaptin Bio has $0.07 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.